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Abstract
A defining feature of inflammation is the accumulation of innate immune cells in the tissue that
are thought to be recruited from the blood. We reveal that a distinct process exists in which tissue
macrophages undergo rapid in situ proliferation in order to increase population density. This
inflammatory mechanism occurred during T helper 2 (Th2)-related pathologies under the control
of the archetypal Th2 cytokine interleukin-4 (IL-4), and was a fundamental component of Th2
inflammation because exogenous IL-4 was sufficient to drive accumulation of tissue macrophages
through self-renewal. Thus, expansion of innate cells necessary for pathogen control or wound
repair can occur without recruitment of potentially tissue-destructive inflammatory cells.
Recruitment of leukocytes from the blood is the key feature of inflammatory responses to
tissue damage or infection. Prominent in this cascade is the rapid influx of granulocytes and
monocytes that subsequently differentiate into inflammatory macrophages and/or dendritic
cells (DC) (1, 2). This paradigm of classical ‘type-1′ inflammation is firmly grounded in
processes elicited by microbial infection or necrotic cell death (2). Inflammation driven by
helminth infection or allergy represents a distinct challenge to the immune system, and is
characterized by the recruitment of cells that produce the cytokine IL-4, including
eosinophils, basophils, and CD4+ Th2 cells (3, 4). Like classical inflammation, ‘type-2′
inflammation also results in the accumulation of large numbers of macrophages in the
affected tissues, (3, 5-7), yet despite this IL-4 and Th2 responses are often regarded as ‘anti-
inflammatory’.
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A key distinguishing feature of macrophages in type-2 inflammation is their polarization
towards an alternative (also known as M2) state of activation, mainly driven by IL-4 and
IL-13 and characterized by expression of a distinct repertoire of molecules including
arginase I, resistin-like molecule alpha (RELMα) and Ym1/2 (8). It has been widely
assumed (1, 8) that accumulation of alternatively activated macrophages occurs through a
process of recruitment similar to macrophage influx during classical inflammation.
Supporting this view, depletion of blood monocytes impairs recruitment of mucosal M2
macrophages during gastro-intestinal nematode infection (5). The intestinal environment
presents unique challenges for the study of type-2-driven inflammation, however, because
commensal bacteria may act as a classical trigger for monocyte influx.
M2 macrophages accumulate independently of monocytes
To examine type 2 inflammatory processes we profiled cell recruitment during infection
with a nematode that resides within ‘sterile’ tissues. The rodent filarial nematode
Litomosoides sigmodontis induces strongly Th2-biased responses (fig. S1A), and drives
alternative macrophage activation in the pleural cavity (Fig. 1A), after migrating there from
the skin (Fig. 1B). For comparison, intra-thoracic injection of thioglycollate was used as a
benchmark of the classical inflammatory cascade (9), because when injected, it induces
recruitment of macrophages to the pleural cavity. Indeed, thioglycollate injection resulted in
the rapid influx of neutrophils (Gr-1high/Ly-6Ghigh) and Gr-1intermediate (int)/Ly-6Chigh
monocytes, leading to accumulation of large numbers of F4/80+ macrophages by day 3 (Fig.
1C and fig. S1B). In contrast, L. sigmodontis infection triggered very little neutrophil or
Gr-1int/Ly-6Chigh monocyte recruitment to the pleural cavity during the first 15 days after
infection (Fig. 1D and fig. S1C), even though larvae arrive at this site between 3 and 6 days
post-infection (Fig. 1B). Despite this, large numbers of F4/80+ macrophages gradually
accumulated in the cavity after day 6 post-infection (Fig. 1D), accompanied by their
conversion to an alternatively activated phenotype (Fig. 1A). There was also a striking
difference in surface phenotype of the macrophage populations elicited by nematode
infection compared to classical inflammation: those elicited by infection expressed levels of
F4/80 similar to resident F4/80high macrophages from naïve tissues (fig. S1C), whereas
those induced by thioglycollate expressed low F4/80 levels (fig. S1B), which is
characteristic of macrophages recruited to the serous cavities under inflammatory conditions
(10).
To determine the role of monocytes in macrophage accumulation, we injected clodronate-
loaded (CL) liposomes intravenously (i.v.). CL-liposomes block tissue infiltration by
macrophages in a variety of inflammatory settings (5, 11, 12). This procedure depletes both
Gr-1int/Ly-6Chigh monocytes, which are the precursors of F4/80low inflammatory
macrophages recruited during classical inflammation, and Gr-1−/Ly-6C− monocytes, which
have been proposed as precursors of both alternatively-activated and tissue resident
macrophages (1, 13). Consistent with expectation, treatment with CL-liposomes blocked the
accumulation of macrophages in the pleural cavity induced by thioglycollate injection (Fig.
1E). In contrast, administration of CL-liposomes during the period when macrophages
accumulate in the cavity (Fig. 1F), or when worms first enter the cavity (fig. S2), had no
effect on either the number of pleural macrophages at day 10 post-L. sigmodontis infection
or the frequency of those expressing alternative activation markers. Macrophage
accumulation occurred despite almost complete removal of Gr-1−/Ly-6C− monocytes from
the blood throughout the entire period after CL-liposome treatment and transient depletion
of Gr-1int/Ly-6Chigh monocytes (Fig. 1G).
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Macrophages proliferate in situ
These data raised the possibility that the large increase in macrophages seen during infection
was the result of expansion of the resident population rather than blood cell recruitment.
Whilst terminal differentiation of most mammalian cells typically results in reduced
proliferative capacity, there is evidence that cells of the mononuclear phagocyte system can
self-replicate in the periphery during development (14) or to maintain the tissue resident
population (15, 16), but not as a classical inflammatory mechanism. Accordingly, on
average 17% of resident pleural macrophages in naïve mice were positive for Ki67, a marker
of proliferation expressed throughout cell-cycle, and 1% were in S-phase, as measured by a
3hr pulse of BrdU (Fig. 2A&B and fig. S3A). In contrast, less than 2% of thioglycollate-
elicited macrophages expressed Ki67 and only 0.2% were in S-phase (Fig. 2A).
Remarkably, pleural macrophages isolated ten days after infection with L. sigmodontis
exhibited a substantial increase in the frequency of dividing cells. On average 38% of cells
in the pleural cavity were positive for Ki67 and 6% were in S-phase (Fig. 2B). BrdU+
macrophages seen in the pleural cavity were not recruited from the blood because no blood
monocytes incorporated BrdU in this 3 hour period (fig. S3B).
To determine whether macrophage proliferation occurs in a distinct type-2 setting, we
looked in the peritoneal cavity following surgical implantation of the human parasitic filarial
nematode Brugia malayi. Incision and suture of the abdominal wall without parasite
implantation was used to control for the surgical procedure and provides a model of
incisional wounding that is characterized by IL-4Rα-dependent alternative macrophage
activation (17). Both implantation of B. malayi and surgery alone resulted in an increased
frequency of BrdU+ and Ki67+ peritoneal macrophages, although this was only maintained
following parasite infection (fig. S4), when Th2 cells become activated (17). Ki67+
macrophages have also been observed in the lungs of hookworm infected mice (7) and
epidermal langerhans cells up-regulate proliferation during atopic dermatitis (14) supporting
the notion that macrophage proliferation is a characteristic common to various type-2
inflammatory settings.
IL-4 instructs proliferative expansion
IL-4 is important for macrophage accumulation during numerous helminth infections (5, 6).
We thus infected IL-4-deficient mice with L. sigmodontis to test the requirement for IL-4 in
proliferative expansion of tissue macrophages. Significantly fewer macrophages from IL-4-
deficient mice were capable of proliferating, as determined by BrdU incorporation, leading
to a failure of these cells to accumulate in the pleural cavity (Fig. 2C). As expected,
macrophages that were present in IL-4-deficient mice were also unable to M2 activate,
whereas worm burdens were indistinguishable between strains at this early stage of
infection, as previously described (18). To demonstrate that IL-4 drives macrophage
proliferation in vivo, mice were injected via the intraperitoneal (i.p.) route with recombinant
IL-4 complexed to IL-4 antibody (IL-4c), which increases the bioactive half-life of the
cytokine (19). Delivery of IL-4c to naïve mice led to an elevation in peritoneal cellularity
over a 4 day period that was due primarily to increased macrophage numbers, all of which
exhibited an alternative activation phenotype (Fig. 3A). IL-4-elicited macrophages
expressed very high levels of F4/80 (mean fluorescence intensity (MFI) of 7300 ± 680
versus 4900 ± 380 in PBS-treated controls; mean ± SEM) and neither inflammatory
monocytes nor neutrophils were recruited (fig. S5), consistent with a process distinct from
classical inflammation (2, 10). Critically, the rate of macrophage proliferation was increased
compared to mice receiving PBS alone (Fig. 3A), whereas no proliferation or accumulation
was observed in IL-4Rα-deficient mice (fig. S6). Thus, delivery of exogenous IL-4 was able
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to mimic the induction of proliferation and accumulation of macrophages observed during
type-2 infection.
Macrophage proliferation in response to IL-4c was not restricted to the peritoneal cavity.
There was an increase in number and frequency of Kupffer cells in the liver (Fig. 3B) as
previously shown (19), and the number of macrophages in the pleural cavity (Fig. 3C) and
both of these populations exhibited increased incorporation of BrdU (Fig. 3, B and C). Thus,
IL-4 can induce tissue macrophage proliferation in diverse body tissues and we propose that
in an environment with high IL-4 the tissue macrophage population will undergo extensive
proliferation.
Self-renewal of resident tissue macrophages
To establish definitively whether IL-4-driven accumulation of tissue macrophages is due to
enhanced turnover of the resident population, we utilized a modified technique for creating
bone marrow chimeric animals (20). Engraftment of bone marrow cells into lethally
irradiated mice results in the replacement of most resident peritoneal macrophages by cells
from transplanted bone marrow (16, 20). In the modified protocol, the upper body of Cd45.1
congenic mice was shielded during irradiation to protect resident pleural macrophages from
harmful effects of direct exposure while allowing engraftment of donor CD45.2+ bone
marrow. Mice were reconstituted for 8 weeks before i.p. injection of IL-4c or PBS, or intra-
thoracic injection of thioglycollate. As expected, partial shielding led to a mixed chimerism
in peripheral blood monocytes (Fig. 3D) and granulocytes (fig. S7) in all groups of mice,
with approximately 25% to 30% of donor origin. In contrast, only 3% of pleural
macrophages were of donor origin in PBS-injected mice (Fig. 3D), which demonstrated that
little replacement of these cells occurred from the bone-marrow under steady-state
conditions. Despite a 3-fold increase in cell number, the same low-level chimerism
(approximately 3% donor-derived cells) was observed in pleural cavity macrophages of
mice treated with IL-4c (Fig. 3D). Identical data were obtained for pleural macrophages
from L. sigmodontis-infected chimeric mice (fig. S8). In contrast, macrophages elicited by
injection of thioglycollate exhibited a high frequency of chimerism indistinguishable from
that observed in blood monocytes and consistent with their differentiation from newly
recruited cells of bone-marrow origin (Fig. 3D). These data reveal that IL-4 and filarial
nematode infection elicit macrophages by expansion of the tissue resident population,
independent of recruitment of bone marrow-derived precursor cells.
Type-1 and type-2 immunity represent ancient innate pathways with fundamentally different
purposes; one controls microbial pathogens (21) and the other macroparasites (22). Profound
differences in amino acid utililization (23) and energy metabolism (24) of polarized
macrophage populations illustrates the broad divergence of these pathways. Similarly, the
IL-4-driven process of proliferative expansion described here contrasts sharply with the
well-defined classical inflammatory process of recruitment (2) that predominates during
type-1 infections (21). The capacity for IL-4-driven proliferation to achieve similar cell
numbers to classical cell recruitment (Fig. 3C) suggests that this is a fundamental alternative
inflammatory pathway. To verify that rapid proliferative expansion of macrophages
represents an innate mechanism of inflammation, we injected RAG-1-deficient mice with
IL-4c. Just as thioglycollate induced macrophage recruitment occurs normally in RAG-1-
deficient mice (17), IL-4c-mediated proliferative expansion was unaltered (Fig. 3E). These
data reveal that accelerated macrophage turnover is an innate response to IL-4, analogous to
the classical inflammatory response to pro-inflammatory cytokines. In natural settings, the
source of IL-4 will depend upon the location and stage of type-2 inflammation, and can be
innate IL-4 producing cells, or adaptive Th2 cells, as illustrated previously using the surgical
wounding or B. malayi peritoneal implant models, respectively (17).
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Proliferation of recruited tissue macrophages
Classical inflammatory stimuli such as microbial insult frequently co-localize with IL-4
production. To assess the impact of IL-4 in a setting where macrophages are actively
recruited by classical stimuli, we simultaneously injected thioglycollate and IL-4c into the
peritoneal cavity. Injection of thioglycollate in the presence of IL-4 induced the
accumulation of macrophages expressing low levels of F4/80 (fig. S9), indicative of a
recruited monocyte-derived population (10). In a separate experiment, proliferating M2
macrophages elicited by intra-pleural injection of thioglycollate in combination with IL-4c
i.p. were confirmed to be of blood origin using the modified bone marrow chimeric animals
described earlier (fig. S10)(20). Critically, thioglycollate-elicited monocyte-derived
macrophages had the capacity to proliferate and become alternatively activated following
treatment with IL-4 (Fig. 4 and fig. S10). Such a situation of mixed recruitment/expansion is
likely to apply during infection with gastro-intestinal nematodes where, despite evidence of
recruitment from the blood, the total number of macrophages that accumulate in the gut
mucosa is far reduced in IL-4-deficient mice (5). Collectively, our data demonstrate that
both resident and recruited macrophages can alternatively activate and be driven to
proliferate by a Th2 environment in vivo. Thus, there is neither a specific precursor for M2
macrophages nor is proliferative capacity restricted by lineage.
Two modes of inflammation
The obvious benefit of classical inflammation is the rapidity with which large numbers of
macrophages can accumulate in the tissues but the maintenance of a circulating precursor
pool throughout the body is energetically costly. In contrast, the slower mechanism of local
expansion in type-2 inflammation does not require enhanced bone marrow activity (Fig. 3D)
and may deliberately avoid inflammatory cell recruitment and the associated potential for
tissue damage. Indeed, IL-4 can actively block granulocyte recruitment during delayed-type
hypersensitivity (25) and instruct macrophages to down-regulate production of pro-
inflammatory chemotactic factors (26). This would be of particular benefit during wound
healing, for example, where type 2-activated macrophages accelerate repair (22, 27, 28) and
sustained classical inflammation results in a failure to heal (29, 30). Thus, we propose that
proliferation at site is an alternative mechanism of inflammation that allows macrophages to
accumulate in sufficient numbers to perform critical functions such as parasite sequestration
or wound repair in the absence of potentially damaging cell recruitment. This has broad
therapeutic implications in settings where Th2-driven macrophages have key positive or
negative function, such as in wound healing, autoimmunity or the tumor micro-environment.
Summary
We have discovered that two distinct innate processes exist through-which macrophages
colonize tissues during inflammation; recruitment of monocytes controlled by classical
inflammatory stimuli and rapid proliferation of the tissue resident population that is
orchestrated by IL-4 and occurs independently of recruitment from the hematopoietic
pool.
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Fig. 1.
Alternatively activated macrophages accumulate independently of blood monocytes. (A)
Proportion of pleural cavity macrophages staining positive for RELMα following infection
with L. sigmodontis and representative flow cytograms gated on CD11b+ Siglec-F− cells for
clarity. N = naïve. (B) Pleural cavity worm burden from mice in (A). (C) Pleural cavity cells
elicited upon intra-thoracic injection of thioglycollate or (D), after infection with L.
sigmodontis, using flow cytometric gating schemes shown in fig. S1, D and E. N = naïve.
(E) Total pleural macrophages elicited by thioglycollate after i.v. injection of PBS, or CL-
liposomes from 2 days prior (D -2) or on the day of (D 0) thioglycollate injection. (F) Total
pleural macrophages and the proportion producing RELMα on day 10 post-L. sigmodontis
infection after daily i.v injection of CL-liposomes or PBS from days 6-9. (G) Frequency of
Gr-1−/Ly-6C− CD115+ (B1) or Gr-1int/Ly-6Chigh CD115+ (B2) monocytes in CD11b+ blood
leukocytes on day 3 and 10 post-L. sigmodontis infection after daily i.v injection of PBS or
CL-liposomes from days 2-5. Values in italics represent the mean ± SEM of 8 mice. (A-G)
All results are representative of 2-3 independent experiments. Graphs present mean ± SEM
of 3-8 mice. (C and D) *P <0.05, **P <0.01 and ***P <0.001, as determined using Kruskal-
Wallis test, with Dunn’s post-test comparing all groups. (E) ***P <0.001, as determined
using one-way analysis of variance (ANOVA) with Tukey’s post-test for multiple
comparisons.
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Fig. 2.
Type-2 inflammation drives in situ proliferation of tissue macrophages. (A) Flow-cytometric
analysis of Ki67 expression or BrdU incorporation by pleural macrophages from naïve mice
or 3 days post-thioglycollate (Thio) injection. BrdU was administered 3 hours prior to
analysis. Gating schemes for Ki67 and BrdU analysis are shown in fig, S1B and 3A,
respectively. Results are pooled data from 2 independent experiments with between 8 and 11
total mice per group. (B) As (A) but BrdU injection and analysis of cells was performed on
day 10 post-infection with L. sigmodontis. Results are pooled data from 2 independent
experiments with between 5 and 11 total mice per group, and are representative of at least 3
further independent experiments. (C) Total pleural macrophages and the proportion staining
positive for BrdU and RELMα from naïve and day 10 L. sigmodontis-infected C57BL/6
(WT) and Il4−/− (−/−) mice, as determined by flow cytometry. Data are representative of two
independent experiments. Graphs present mean ± SEM of 7-8 mice per group. (A and B)
**P <0.01 and ***P <0.001, as determined by 2-tailed t test. (C) *P <0.05, **P <0.01 and
***P <0.001, as determined using one-way ANOVA with Tukey’s post-test for multiple
comparisons.
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Fig. 3.
Macrophage proliferation is an innate tissue hyperplasia triggered by IL-4. Mice were
treated i.p. with PBS or IL-4c on days 0 and 2 and analyzed on day 4. (A) Composition of
peritoneal cells, the proportion of peritoneal macrophages positive for BrdU, Ki67 or
RELMα, and representative flow cytograms depicting all peritoneal cells. Graphs present
mean ± SEM of 5 mice per group; representative of 10 independent experiments. (B) Total
F4/80+ CD11blow Kupffer cells, BrdU incorporation by Kupffer cells, and gating scheme
depicting Kupffer cells and BrdU versus MHCII staining as determined by flow cytometry.
Data shown are of livers pooled from 3 PBS-treated mice, or individual IL-4c-treated mice,
and are combined from two independent experiments. (C) As (A) but in the pleural cavity.
Graph presents mean ± SEM of 3 mice per group for cell composition, whereas BrdU
incorporation is of pooled cells from 3 PBS-treated mice, or individual IL-4c-treated mice.
Data are representative of 5 independent experiments. (D) Flow cytometric analysis of
chimerism of blood monocytes and pleural macrophages and number of pleural
macrophages in Cd45.1 congenic mice given CD45.2+ bone marrow cells after partial-body
irradiation, and subsequently treated with PBS or IL-4c i.p., or intra-thoracic thioglycollate
at week 8 post reconstitution. Representative CD45.1 and CD45.2 staining gated on CD11b+
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CD115high blood monocytes or F4/80+ pleural macrophages. Graphs depict mean ± SEM of
4 mice per group; representative of 2 independent experiments. (E) As (A) but in C57BL/6
(WT) and Rag1−/− (−/−) mice. Graphs depict mean ± SEM of 3-4 mice per group;
representative of 2 independent experiments.
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Fig. 4.
IL-4 triggers inflammatory macrophages to proliferate and alternatively activate. The
proportion of peritoneal macrophages positive for BrdU, Ki67 or RELMα are shown, and
representative flow cytograms depicting all peritoneal cells, from mice injected i.p.
simultaneously with thioglycollate and PBS or IL-4c. IL-4c and PBS injections repeated on
day 2 and analysis performed on day 4. Data are representative of two independent
experiments, with 5 mice per group.
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